Novo Holdings’ Post

From new options for feline diabetes to the first drug to treat acute pancreatitis in dogs, 2023 was a huge year for veterinary drugs. Keeping up with all the details wasn't easy. We created this guide to help. Download your free copy for a refresher on dosing, contraindications, and more for these new drugs and therapeutics, including fuzapladib, molidustat, and mAbs to treat parvovirus and cancer. #VetMed #VeterinaryDrugs #EBook #VeterinaryPharmacy

Amgis Lifescience Ltd: Leading the Way in Veterinary APIs. Introduction Amgis Lifescience Limited is a trusted name in the pharmaceutical industry, specializing in high-quality Active Pharmaceutical Ingredients (APIs) for veterinary use. With a commitment to excellence, innovation, and animal health, Amgis offers a comprehensive range of APIs that meet global standards. Our Veterinary API Products 1. Albendazole - CAS Number: 54965-21-8 - Pharmacopeia:IP/BP/EP/USP - ODMF:Yes - Therapeutic Use: Anthelmintic Albendazole, a broad-spectrum anthelmintic, effectively combats parasitic infections in animals. It is widely used to treat gastrointestinal worms, lungworms, and liver flukes. 2. Salbutamol Sulphate - CAS Number: 51022-70-9 - Pharmacopeia: EP/BP - Therapeutic Use: Anti-Asthmatic Salbutamol Sulphate, a bronchodilator, is crucial in managing animal respiratory conditions. It provides relief from bronchospasms and improves breathing. 3. Ricobendazole - CAS Number: 54029-12-8 - Pharmacopeia: IH/BP - ODMF: Yes - Therapeutic Use: Anthelmintic Ricobendazole is a potent anthelmintic that targets both adult and larval stages of parasitic worms. It ensures optimal health by controlling worm infestations. 4. Fenbendazole - CAS Number: 43210-67-9 - Pharmacopeia: IP/BP/EP/USP - ODMF: Yes - Therapeutic Use: Anthelmintic Fenbendazole is a versatile anthelmintic effective against nematodes, cestodes, and trematodes. It is a go-to choice for deworming protocols. 5. Oxfendazole - CAS Number: 53716-50-0 - Pharmacopeia: IP/BP/EP/USP - ODMF: Yes - Therapeutic Use: Anthelmintic Oxfendazole, with its broad-spectrum activity, tackles gastrointestinal parasites and liver flukes. It ensures healthier livestock and pets. 6. Nitroxynil - CAS Number: 1689-89-0 - Pharmacopeia: BP/IH - Therapeutic Use: Anthelmintic Nitroxynil is specifically effective against liver flukes and other trematodes. It promotes liver health and overall well-being. 7. Triclabendazole - CAS Number: 68786-66-3 - Pharmacopeia: EP/BP/USP - Therapeutic Use: Anthelmintic Triclabendazole targets liver flukes and fascioliasis. Its efficacy makes it indispensable in livestock management. 8. Butaphosphan - CAS Number: 17316-67-5 - Pharmacopeia: BP/IH - Therapeutic Use: Anthelmintic Butaphosphan, an essential nutrient, supports metabolism and energy production. It plays a vital role in maintaining animal health. Why Choose Amgis? - Quality Assurance: Our APIs adhere to the highest quality standards. - Global Reach: We serve clients worldwide, ensuring timely delivery. - Expertise: Decades of experience in the pharmaceutical industry. - Commitment: We prioritize animal welfare and sustainable practices. Choose Amgis Lifescience Limited for reliable, effective, and safe Veterinary APIs. Let's enhance animal health together! 🐾🌟 For further information, please contact me through ✉️ u.u.commercialoutsourcing@outlook.com or 📱+58 412 4770974 | ☎️ +1 574 263 4028

Vetbiobank reaches another major Milestone with the Successful Submission of its Centralised Marketing Authorisation Application for Its “Best in Class” Canine Neonatal Stem Cells product for treating Canine Osteoarthritis !   We are thrilled to announce that thanks to the exceptional dedication of our teams at Vetbiobank, and the efficient collaboration with the Argenta regulatory team, we have successfully submitted our Marketing Authorisation Application (MAA) to the European Medicines Agency according to our planned schedule.   The highly favorable results of our multicenter pivotal Phase III study evaluating the efficacy of our cell therapy VBX-101 for canine osteoarthritis, combined with the robustness of our #bioproduction platform, promise a successful outcome with regulatory authorities, veterinarians, dogs, and their owners.   Based in Lyon, Vetbiobank is a pharmaceutical establishment specializing in the development and #biomanufacturing of #CellTherapies for veterinary medicine, focusing on the treatment of chronic inflammatory diseases in cats, dogs, and horses.   More to come about the product itself! A big and warm “Thank You” to our team and to all stakeholders involved in this accomplishment, for their dedication and remarkable work or support! 🙏 Harald EGELHOFER; Mathieu Danjou; Rodolphe Rakic; Nathalie Saulnier; Marine FEBRE; Clément ROBERT; Tiffany Thevenard; Violaine TANGUY but also Sabine Richter; Annegret Wuensch; Patxi Sarasola; Maria Churruca; David Sabaté and to finish PBA - Paris Business Angels; BADGE Business Angels des Grandes Ecoles Angels Santé; HARA (Health Angels Rhône Alpes); Holnest; Angelor; Savoie Mont Blanc Angels - SAMBA; Bpifrance ; Sowefund  #Biotechnology #Veterinary #Innovation #AnimalHealth #CanineOsteoarthritis #MesenchymalStemCells #RegenerativeMedicine #Veterinary  

🙌 A successful veterinary research study in canine autoimmune diseases. Dogs with discoid lupus erythematosus (DLE), a difficult chronic inflamed skin condition, respond well to cannabinoid therapy. Wonderful news! 🐶 Read on... #autoimmunediseases #veterinaryscience #immunesystem #lupus #inflammation #research

FDA CVM lays out innovation plan for new animal, veterinary products Addressing drug shortages and bringing innovative products to market are priorities in its Animal and Veterinary Innovation Agenda ِThe Food and Drug Administration’s Center for Veterinary Medicine (FDA CVM) announced its Animal and Veterinary Innovation Agenda last fall. As part of this effort, the FDA CVM intends to launch a Gene Editing Regulatory Science Council comprising experts from the FDA’s human, animal, and plant programs. Speaking during the AVMA House of Delegates regular winter session, held January 5-6 in Chicago, Dr. Colonius referenced the FDA’s recent approval of two new breakthrough treatments for sickle cell disease, one of which is the first medicine to be approved in the U.S. that uses the gene-editing tool CRISPR-Cas9.  Key objectives of the FDA CVM agenda are supporting technologies and products that address high-priority needs; aligning regulatory pathways to the modern landscape; enhancing the agency’s One Health workforce for the future of innovation; and identifying and addressing gaps specific to new technologies and emerging health threats. Ways in which these goals will be realized include fast-tracking certain products, such as biotechnologies, by offering scientific assistance to developers and finding ways to offer faster review times to speed innovative products to market. The FDA CVM will also explore modernizing regulatory pathways to create smart and agile frameworks that support and spur innovation, Dr. Colonius said. The FDA CVM intends to launch a Gene Editing Regulatory Science Council comprising experts from the FDA’s human, animal, and plant programs to look at common emerging science in this space and ways to address risks, such as off-target effects. He said doing so would truly put One Health into action and bring more products to market that address critical animal and human health needs. Additionally, the innovation program calls for recruiting, retaining, and continuing to develop world-class scientific and technical talent and the creation and implementation of an FDA One Health Code of Practice. The FDA CVM will develop specific, measurable actions to adapt the center’s operational practice, risk prioritization, and strategic planning to integrate human, animal, and environmental scientific areas of focus to address complex public health problems. The FDA CVM will form an Innovation Exploration Task Force to work across the center to develop and implement methods of monitoring emerging technologies from all sectors—including biomedical products and novel food ingredients for both animals and humans—that can impact the FDA CVM’s regulatory work. And finally, the FDA CVM will research emerging technologies that will allow the center to better align its work with the attributes of those technologies. Source: American Veterinary Medical Association

I recently attend the Veterinary Biologics Training Program (VBTP) hosted by the Institute for International Cooperation in Animal Biologics (IICAB) and learned a lot about regulations surrounding policy, evaluation, licensing, inspection, and compliance of biologics for use in animals! IICAB was established in 1995 by the United States Department of Agriculture (USDA) Animal and Plant Health Inspection Service (APHIS) and Iowa State University. This institute works to improve the availability, safety, efficacy and use of veterinary biologics around the world. One division of APHIS, the Center for Veterinary Biologics (CVB) regulates biologics to ensure they are available for the diagnosis, prevention, and treatment of animal diseases. Biologics, or biological products, act primarily via the immune system to treat animals. These include vaccines, bacterins, allergens, antibodies, immunostimulants, certain cytokines, and antigenic components of live organisms, among others. The CVB was enacted for consumer protection and began in 1913 following the Virus-Serum-Toxin Act. Since then, there have been other federal regulations and policy documents developed to provide further guidance. The CVB ensures each biologic is consistently pure, safe, potent, and effective so once approved it is available for use. They ensure purity by verifying there are no extraneous agents present and ensure safety by verifying the product is stable and safe for use in animals as well as the environment. The CVB validates each batch (or serial) of product is consistent and maintains potency. Finally, CVB makes certain that each biologic is effective and makes an impact on animal’s immune system in a way that supports the regulatory claim. For more information, including a list of approved products, further training, and employment opportunities, visit the Center for Veterinary Biologics website. https://lnkd.in/eui_vVag

Are you using #ILE lipid in your #toxicology patients? Check out this VETgirl #veterinary blog on the use in your poisoned patients! ASPCA ASPCA Animal Poison Control Center https://lnkd.in/g3WWuEpt

𝗕𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗕𝗼𝘂𝗻𝗱𝗮𝗿𝗶𝗲𝘀 𝗶𝗻 𝗩𝗲𝘁𝗲𝗿𝗶𝗻𝗮𝗿𝘆 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀 – 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 𝘀𝗲𝗿𝗶𝗲𝘀 by Gattefossé Pharmaceuticals. See the overview of the four parts of the series. #veterinary #formulation #excipients

𝗕𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗕𝗼𝘂𝗻𝗱𝗮𝗿𝗶𝗲𝘀 𝗶𝗻 𝗩𝗲𝘁𝗲𝗿𝗶𝗻𝗮𝗿𝘆 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀 – 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 𝘀𝗲𝗿𝗶𝗲𝘀 by Gattefossé Pharmaceuticals. See the overview of the four parts of the series. #veterinary #formulation #excipients

I'm thrilled to share that one of my master’s degree products has been published in the International Journal of Pharmaceutics! 📚 Our research, titled "Pimobendan controlled release guar gum printlets: Tailoring drug doses for personalised veterinary medicines" delves into developing controlled-release flavored printlets containing pimobendan, a veterinary drug only, for treating a heart condition in dogs. You can read the full article at this link: https://lnkd.in/d6bPwu2W I invite you all to dive into our findings and share your thoughts. #3dprinting #veterinarymedicine #ijp #pimobendan #personalizedmedicine #vet